CME

Achievement of National Quality Standards in HER2-positive Breast Cancer

By January 8, 2016February 14th, 2017No Comments
Achievement of National Quality Standards in HER2-positive Breast Cancer: A Pilot Study on the Impact of Certified Education Plus a Novel Care Planning Tool

Achievement of National Quality Standards in HER2-positive Breast Cancer: A Pilot Study on the Impact of Certified Education Plus a Novel Care Planning Tool

FOR REFERENCE ONLY
Release Date:
 July 27, 2015 
Expiration Date:
 July 27, 2016

ESTIMATED TIME TO COMPLETE ACTIVITY:

1.75 hours

Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc. (formerly On Q Health)
Jointly provided by Postgraduate Institute for Medicine and Carevive Health, Inc.

Download PDF    Take Post-test

TARGET AUDIENCE

The target audiences for these activities are medical oncologists, physician assistants, nurse practitioners, oncology nurses, nurse navigators, and palliative/symptom management teams.The target audiences for these activities are surgeons, surgical oncologists, medical oncologists, physician assistants, nurse practitioners, and oncology nurses.

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

  • Develop evidence-based treatment approaches for patients diagnosed with – breast cancer in the neoadjuvant, adjuvant and metastatic settings
  • Recognize quality measures associated with the management of HER2-positive breast cancer
  • Demonstrate collaboration with the multi-disciplinary cancer team to meet quality standards relevant to the management of HER2-positive breast cancer
  • Formulate personalized care plans for patients with HER2-positive breast cancer to provide education and recommendations/referrals to manage cancer and cancer-related symptoms
  • Recognize the evolving evidence on the management of chemotherapy-induced nausea and vomiting, diarrhea, chemotherapy-induced peripheral neuropathy, fatigue, lymphedema, bone health, weight gain, psychosocial distress (anxiety, fear of recurrence), menopausal symptoms, cardiotoxicity, mouth sores, and diarrhea
  • Provide appropriate care and counsel for patients and their families

CO-CHAIRS

Douglas W. Blayney, MD
The Stanford University Medical Center

Paul Jacobsen, PhD
Moffitt Cancer Center

FACULTY

Linden Spital, NP
Lancaster General Health

Jeannine M. Brant PhD, APRN, AOCN
Billings Clinic Inpatient Cancer Care

Laura Zitella, MS, RN, ACNP-BC, AOCN
Stanford University Medical Center

Jacquelyn M. Powers, MS, CGC
Abramson Cancer Center, University of Pennsylvania

Gloria ‘Lita’ Smith
University of Michigan

Rita Wickham, PhD, RN, CHPN, AOCN
Rush University Medical Center College of Nursing

PHYSICIAN CONTINUING MEDICAL EDUCATION

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and On Q Health, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING MEDICAL EDUCATION

Credit Designation

This educational activity for 1.6 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by theAmerican Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related material that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Douglas W. Blayney, MD No real or apparent conflict of interest to report.
Paul Jacobsen, PhD No real or apparent conflict of interest to report.
Linden Spital, NP No real or apparent conflict of interest to report.
Jeannine M. Brant PhD, APRN, AOCN Consulting Fees, Insys; Speakers’ Bureaus, Insys, Genentech.
Laura Zitella, MS, RN, ACNP-BC, AOCN Consulting Fees, Teva, Prometheus, VATA Medical Supply.
Jacquelyn M. Powers, MS, CGC, Consulting Fees/Advisory Board, Pathway Genomics.
Gloria ‘Lita’ Smith Speakers’ Bureau, Genentech BioOncology
Rita Wickham, PhD, RN, CHPN, AOCN No real or apparent conflict of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Carevive Systems, Inc. planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Gilead Sciences; Karen Hammelef, DNP, RN, Speakers’ Bureau, Novartis Pharmaceuticals Corporation.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME credit for this activity. During the period July 27, 2015 through July 27, 2016 participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 10752.. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

MEDIA

Monograph

HARDWARE AND SOFTWARE REQUIREMENTS

CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Download PDF    Take Post-test

This activity is supported by an independent educational grant from Genentech BioOncology. Activity ID: G-403

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.